8:01 AM ET
8-K
Clinical Trial Data
Pasithea Therapeutics Clinical Trial Data
Pasithea Therapeutics announced positive initial Phase 1/1b clinical data for PAS-004 in patients with neurofibromatosis type 1 (NF1), showing that all 15 evaluable participants experienced reductions in cutaneous neurofibroma (cNF) surface area. The company also reported that the FDA has cleared its Investigational New Drug (IND) application to proceed with a Phase 2 trial of PAS-004 in adults with NF1-associated cNF.